Delivery Order SPE2DB22D7058-SPE2DB23FSUK3
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of Entecavir 0.5 mg tablets. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and the DLA, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $1,758.86 Firm Fixed Price Delivery Order is for the supply of 4564950562 - Entecavir 0.5 mg Tablet 30s, with a period of performance through June 21, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,933.51, is for the delivery of 30-count tablets of the medication Entecavir 0.5 mg. The contract has a firm fixed price pricing type and an ultimate completion date of March 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The $4,803.14 firm fixed-price delivery order is for the supply of 4,564,741,586 units of the prescription medication Entecavir 0.5 mg tablets. The contract has an ultimate completion date of May 30, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award to AmerisourceBergen Drug Corp's Corporate Office division is for the supply of Entecavir 0.5 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical program. The firm-fixed-price delivery order, valued at $2,131.53, was issued under the $999,999,999 DLA Troop Support Medical Indefinite Delivery Contract that runs through December 2025. This contract vehicle enables the DLA to efficiently procure a wide range of pharmaceutical and medical supplies to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,341.22, is for the delivery of Entecavir 0.5 mg tablets. It is a firm fixed-price contract with a period of performance through May 21, 2024. The contract was not set aside for any specific business type. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a federal contract award issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,287.52 firm fixed-price delivery order is for the supply of ENTECAVIR 0.5 MG TABLET 30S, a medication used to treat chronic hepatitis B. The award has an ultimate completion date of February 26, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $7,948.92 for the provision of Entecavir 0.5 mg tablets. The award was made by the Defense Logistics Agency (DLA), with the contract designated as SPE2DB20D3103|SPE2DB23FM5U4. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order valued at $4,489.51 and has a completion date of May 1, 2024. The contract is for the delivery of 4,564,452,240 units of the pharmaceutical product Entecavir 0.5 mg Tablet 30s. This award is not set aside for any particular business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award is a delivery order with a firm fixed price valued at $2,244.95, issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ENTECAVIR 0.5 MG TABLET 30S, with a completion date of August 6, 2024. There was no set-aside designation for this award. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB22D7058Indefinite Delivery Contract
- SPE2DB22D7058-SPE2DB23FSUK3Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division, a subsidiary of Amerisourcebergen Corporation. The $7,916.40 firm fixed price delivery order is for the provision of Entecavir 0.5 mg tablets, a prescription medication. Amerisourcebergen is a major supplier of pharmaceuticals and medical supplies to the U.S. government, with a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of medical products to DLA facilities supporting the Department of Defense worldwide. Amerisourcebergen also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical commodities, valued up to $750,000 through May 2024. The contract has no set-aside designation and was awarded on a full and open competition basis, highlighting Amerisourcebergen's competitive position in the federal pharmaceutical supply market.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 8/24/23 |